@OncoAlert CCC19 in @Lancet: 30-day all-cause mortality was 13%, >2x the mortality of global average. Subgroups ranged from 0% mortality (ECOG=0 with no actively treated comorbidities) to 85% mortality (ECOG performance status of 2 or higher and requiring mechanical ventilation) https://twitter.com/NicoleKuderer/status/1266138458122141697

2/ @Lancet CCC19: General baseline clinical variables independently associated with incre death: older age, male sex, two or more comorbidities that require active therapy, and former smoking status. We had an insufficient number of current smokers to formally assess their risk.

3/ @Lancet #CCC19 Cancer-specific clin factors independently associated with death: ECOG performance=2 or higher, and active (measurable) cancer. If progressing cancer -> five-fold relative risk of dying within 30 days, compared to those in remission. @OncoAlert @gary_lyman

4/ @Lancet #CCC19: Hydroxychloroquine and azithromycin showed no obvious benefit. Harm at min in part due to imbalances in other important clinical risk factors. This indicates the need for prospective study of these drugs. @OncoAlert @gary_lyman @mtmdphd

5/ @Lancet #CCC19: Factors that did not reach significance for death were: race/ethnicity, obesity, or within 4 weeks of surgery or anti-cancer therapy when COVID-19 diagnosed (more data on specific high risk settings needed esp melosuppression and specific therapies & surgeries).

6/ @Lancet #ccc19: Taken together, our results suggest: Fit pts <75 with minor comorbidities carefully can and should proceed with appropriate anti-cancer treatment, whereas those with poor performance status need to have thoughtful conversations about risk vs benefit @OncoAlert

7/ @Lancet #CCC19: Longer follow-up & larger sample size are needed to more completely understand the impact of SARS-CoV-2 on outcomes in patients with cancer, especially to reliably assess specific high risk clinical settings as well as individual cancer therapies. @OncoAlert